ICAAC 2007 Leadership
Discussion among Nine Infectious Disease Specialists
September 2007
Project Objectives
To discuss the latest research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) with key opinion leaders in the field of infectious disease. ICAAC was held in
§ Review drugs being developed against methicillin-resistant Staphylococcus aureus (MRSA) including iclalprim, oritavancin, and ceftobiprole
§ Examine current and future use of Cubicin
§ Discuss the future of doripenem
§ Elucidate any controversy surrounding oral faropenem
§ Evaluate the potential of sitafloxacin, a new fluoroquinolone
§ Explore the ketolides – discuss experience with Ketek and thoughts about cethromycin, the next-generation ketolide in development
§ Review the Rotavirus vaccines – discuss experience with RotaTeq™, and thoughts about Rotarix™, a new vaccine in development
Companies and Products Mentioned in This Report
|
Ticker Symbol |
Company |
Products |
|
|
Arpida Ltd. |
Icalparim (intravenous) |
|
|
Targanta Therapeutics |
Oritavancin |
|
JNJ |
Johnson & Johnson Basilea Pharmaceutica Ltd. |
Ceftobiprole |
|
CBST |
Cubist Pharmaceutical |
Cubicin® (daptomycin) |
|
|
Daiichi Pharmaceutical |
Sitafloxacin |
|
JNJ |
Johnson & Johnson/Ortho-McNeil |
Doripenem |
|
RDYN |
Replidyne |
Faropenem |
|
SNY |
Sanofi-Aventis |
Ketek® (telithromycin) |
|
ADLS |
Advanced Life Sciences |
Cethromycin |
|
MRK |
Merck |
RotaTeqTM |
|
GSK AVAN |
GlaxoSmithKline Avant Immunotherapeutics |
RotarixTM |
Inclusion Criteria and Respondent Demographics
Nine key opinion leaders in the field of infectious disease that are board certified and have 2 to 30 years of experience post-training.
Hospitals Represented
|
Academic Affiliation |
State/Location |
|
|
NC |
|
|
|
|
Columbia University Medical Center/Morgan Stanley Children’s Hospital |
NY |
|
|
IL |
|
|
TN |
|
Harvard Vanguard Medical Associates |
MA |
|
|
VA |
|
|
NY |
|
|
NY |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |